UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Long-Term Side Effects of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia

Current hematologic malignancy reports, 2016-04, Vol.11 (2), p.71-79

2016

Volltextzugriff (PDF)

Improving Outcomes in Chronic Myeloid Leukemia Over Time in the Era of Tyrosine Kinase Inhibitors

Clinical lymphoma, myeloma and leukemia, 2018-11, Vol.18 (11), p.710-723

2018

Volltextzugriff (PDF)

Rationale and motivating factors for treatment-free remission in chronic myeloid leukemia

Leukemia & lymphoma, 2016-12, Vol.57 (12), p.2739-2751

2016

Volltextzugriff (PDF)

Considering baseline factors and early response rates to optimize therapy for chronic myeloid leukemia in chronic phase

Leukemia & lymphoma, 2016-05, Vol.57 (5), p.1002-1014

2016

Volltextzugriff (PDF)

Second-generation BCR-ABL kinase inhibitors in CML

The New England journal of medicine, 2010-10, Vol.363 (17), p.1672

Akard, Luke P

2010

Volltextzugriff (PDF)

High-Dose Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia: High Rates of Rapid Cytogenetic and Molecular Responses

Journal of clinical oncology, 2009-10, Vol.27 (28), p.4754-4759

2009

Volltextzugriff (PDF)

Related peripheral blood stem cell donors experience more severe symptoms and less complete recovery at one year compared to unrelated donors

Haematologica (Roma), 2019-04, Vol.104 (4), p.844-854

2019

Volltextzugriff (PDF)

Impact of Public Reporting of Center-Specific Survival Analysis Scores on Patient Volumes at Hematopoietic Cell Transplant Centers

Transplantation and cellular therapy, 2023-08, Vol.29 (8), p.523-528

2023

Volltextzugriff (PDF)

Evaluating the Impact of a Switch to Nilotinib on Imatinib-Related Chronic Low-Grade Adverse Events in Patients With CML-CP: The ENRICH Study

Clinical lymphoma, myeloma and leukemia, 2016-05, Vol.16 (5), p.286-296

2016

Volltextzugriff (PDF)

Correlations between cytogenetic and molecular monitoring among patients with newly diagnosed chronic myeloid leukemia in chronic phase: post hoc analyses of the Rationale and Insight for Gleevec High-Dose Therapy study

Archives of pathology & laboratory medicine (1976), 2014-09, Vol.138 (9), p.1186-1192

2014

Volltextzugriff (PDF)

Omacetaxine mepesuccinate for patients with accelerated phase chronic myeloid leukemia with resistance or intolerance to two or more tyrosine kinase inhibitors

Haematologica (Roma), 2013-07, Vol.98 (7), p.e78-e79

2013

Volltextzugriff (PDF)

Transplantation of hematopoietic stem cells from the peripheral blood

Journal of cellular and molecular medicine, 2005-01, Vol.9 (1), p.37-50

2005

Volltextzugriff (PDF)

Effects of extensive splenomegaly in patients with myelofibrosis undergoing a reduced intensity allogeneic stem cell transplantation

British journal of haematology, 2008-04, Vol.141 (1), p.80-83

2008

Volltextzugriff (PDF)

A randomized open label exploratory controlled trial of CLT-008 myeloid progenitor cells (MPC) to decrease infections during induction for AML

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.7043-7043

2018

Volltextzugriff (PDF)

Translating Trial-Based Molecular Monitoring Into Clinical Practice: Importance of International Standards and Practical Considerations for Community Practitioners

Clinical lymphoma, myeloma and leukemia, 2011-10, Vol.11 (5), p.385-395

2011

Volltextzugriff (PDF)

Clinical roundtable monograph: Unmet needs in the management of chronic myelogenous leukemia

Clinical advances in hematology & oncology, 2012-12, Vol.10 (12 Suppl 22), p.1-16

2012

Volltextzugriff (PDF)

Transportation of peripheral blood progenitor cell products: effects of time, temperature and cell concentration

Cytotherapy (Oxford, England), 2009, Vol.11 (1), p.79-85

2009

Volltextzugriff (PDF)

Letermovir for Cytomegalovirus Prophylaxis in Hematopoietic-Cell Transplantation

The New England journal of medicine, 2014-05, Vol.370 (19), p.1781-1789

2014

Volltextzugriff (PDF)

Why Don't Hematologists Follow Chronic Myeloid Leukemia Monitoring Guidelines? A Survey Of Practioners In New Jersey and Indiana

Blood, 2013-11, Vol.122 (21), p.5187-5187

2013

Volltextzugriff (PDF)

Exploratory study on the impact of switching to nilotinib in 18 patients with chronic myeloid leukemia in chronic phase with suboptimal response to imatinib

Therapeutic advances in hematology, 2017-01, Vol.8 (1), p.3-12

2017

Volltextzugriff (PDF)

Prediction of engraftment after autologous peripheral blood progenitor cell transplantation: CD34, colony-forming unit-granulocyte-macrophage, or both?

Transfusion (Philadelphia, Pa.), 2007-05, Vol.47 (5), p.817-823

2007

Volltextzugriff (PDF)

Donor Lymphocyte Infusions Used to Treat Mixed-Chimeric and High-Risk Patient Populations in the Relapsed and Nonrelapsed Settings after Allogeneic Transplantation for Hematologic Malignancies Are Associated with High Five-Year Survival if Persistent Full Donor Chimerism Is Obtained or Maintained

Biology of blood and marrow transplantation, 2017-11, Vol.23 (11), p.1989-1997

2017

Volltextzugriff (PDF)

Parsaclisib, a potent and highly selective PI3Kδ inhibitor, in patients with relapsed or refractory B-cell malignancies

Blood, 2019-04, Vol.133 (16), p.1742-1752

2019

Volltextzugriff (PDF)

Longitudinal Study of Adaptation to the Stress of Bone Marrow Transplantation

Journal of clinical oncology, 2000-04, Vol.18 (7), p.1539-1549

2000

Volltextzugriff (PDF)

1 – 25 von 116

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(100)
Mit Volltextzugriff
(103)

Publikationsform

Artikel
(116)

Sprache

Englisch
(116)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

Humans
(57)
Life Sciences & Biomedicine
(54)
Science & Technology
(54)
Hematology
(32)
Adult
(28)
Female
(26)
Middle Aged
(26)
Male
(23)
Aged
(18)
Oncology
(16)
Treatment Outcome
(16)
Biological And Medical Sciences
(15)
Time Factors
(14)
Medical Sciences
(13)
Leukemia, Myeloid, Chronic-Phase - Drug Therapy
(9)
Protein Kinase Inhibitors - Therapeutic Use
(9)
Transplantation
(9)
Aged, 80 And Over
(8)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(8)
Immunology
(8)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Long-Term Side Effects of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia

Improving Outcomes in Chronic Myeloid Leukemia Over Time in the Era of Tyrosine Kinase Inhibitors

Rationale and motivating factors for treatment-free remission in chronic myeloid leukemia

Considering baseline factors and early response rates to optimize therapy for chronic myeloid leukemia in chronic phase

Open-Label Phase II Prospective, Randomized, Controlled Study of Romyelocel-L Myeloid Progenitor Cells to Reduce Infection During Induction Chemotherapy for Acute Myeloid Leukemia

Second-generation BCR-ABL kinase inhibitors in CML

High-Dose Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia: High Rates of Rapid Cytogenetic and Molecular Responses

Related peripheral blood stem cell donors experience more severe symptoms and less complete recovery at one year compared to unrelated donors

Impact of Public Reporting of Center-Specific Survival Analysis Scores on Patient Volumes at Hematopoietic Cell Transplant Centers

Evaluating the Impact of a Switch to Nilotinib on Imatinib-Related Chronic Low-Grade Adverse Events in Patients With CML-CP: The ENRICH Study

Correlations between cytogenetic and molecular monitoring among patients with newly diagnosed chronic myeloid leukemia in chronic phase: post hoc analyses of the Rationale and Insight for Gleevec High-Dose Therapy study

Omacetaxine mepesuccinate for patients with accelerated phase chronic myeloid leukemia with resistance or intolerance to two or more tyrosine kinase inhibitors

Transplantation of hematopoietic stem cells from the peripheral blood

Effects of extensive splenomegaly in patients with myelofibrosis undergoing a reduced intensity allogeneic stem cell transplantation

A randomized open label exploratory controlled trial of CLT-008 myeloid progenitor cells (MPC) to decrease infections during induction for AML

Translating Trial-Based Molecular Monitoring Into Clinical Practice: Importance of International Standards and Practical Considerations for Community Practitioners

Clinical roundtable monograph: Unmet needs in the management of chronic myelogenous leukemia

Transportation of peripheral blood progenitor cell products: effects of time, temperature and cell concentration

Letermovir for Cytomegalovirus Prophylaxis in Hematopoietic-Cell Transplantation

Why Don't Hematologists Follow Chronic Myeloid Leukemia Monitoring Guidelines? A Survey Of Practioners In New Jersey and Indiana

Exploratory study on the impact of switching to nilotinib in 18 patients with chronic myeloid leukemia in chronic phase with suboptimal response to imatinib

Prediction of engraftment after autologous peripheral blood progenitor cell transplantation: CD34, colony-forming unit-granulocyte-macrophage, or both?

Donor Lymphocyte Infusions Used to Treat Mixed-Chimeric and High-Risk Patient Populations in the Relapsed and Nonrelapsed Settings after Allogeneic Transplantation for Hematologic Malignancies Are Associated with High Five-Year Survival if Persistent Full Donor Chimerism Is Obtained or Maintained

Parsaclisib, a potent and highly selective PI3Kδ inhibitor, in patients with relapsed or refractory B-cell malignancies

Longitudinal Study of Adaptation to the Stress of Bone Marrow Transplantation

Suchergebnisse filtern